| WANG, GANG |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
NCT05772104: Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder |
|
|
| Recruiting | 3 | 495 | RoW | Shugan Jieyu Capsules, Shugan Jieyu Capsules Placebo | Sichuan Jishengtang Pharmaceutical Co., Ltd. | Generalized Anxiety Disorder | 02/25 | 06/25 | | |
NCT05093855: Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 2 | 41 | RoW | BDB-001 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 08/23 | 08/23 | | |
NCT06259526: A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression |
|
|
| Recruiting | 2 | 260 | RoW | Placebo group, JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 low-dose group, JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 pills; JS1-1-01 placebo pills, JS1-1-01 high-dose group, JS1-1-01 pills; Duloxetine hydrochloride placebo capsules, Active drug group, JS1-1-01 placebo pills; Duloxetine hydrochloride enteric coated capsule | Tasly Pharmaceutical Group Co., Ltd | Depression | 04/25 | 04/25 | | |
NCT04388982: the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease |
|
|
| Recruiting | 1/2 | 9 | RoW | low dosage MSCs-Exos administrated for nasal drip, mild dosage MSCs-Exos administrated for nasal drip, high dosage MSCs-Exos administrated for nasal drip | Ruijin Hospital, Cellular Biomedicine Group Ltd. | Alzheimer Disease | 08/21 | 08/22 | | |
NCT05103423: Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 1/2 | 50 | RoW | BDB-001 Injection, Placebo | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 07/23 | 07/23 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT05196971: A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression |
|
|
| Completed | 1 | 12 | RoW | HS-10345 84mg, HS-10345, Placebo, HS-10345 Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Treatment Resistant Depressive Disorder | 04/22 | 10/22 | | |
| Recruiting | 1 | 88 | RoW | 2mg KH607 tablets, 5mg KH607 tablets, 10mg KH607 tablets, 20mg KH607 tablets, 30mg KH607 tablets, 40mg KH607 tablets, 50mg KH607 tablets, 60mg KH607 tablets | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | Healthy | 10/24 | 10/24 | | |
NCT06105151: Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers |
|
|
| Recruiting | 1 | 78 | RoW | VV119(SAD), VV119 Placebo(SAD), VV119(FE) | Vigonvita Life Sciences | Schizophrenia | 12/24 | 12/24 | | |
NCT06504290: Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119 |
|
|
| Recruiting | 1 | 32 | RoW | VV119 Placebo （in healthy adult subjects）, VV119 （in healthy adult subjects）, VV119(in adult patients with schizophrenia), VV119 Placebo （in adult patients with schizophrenia） | Vigonvita Life Sciences | Schizophrenia | 07/25 | 07/25 | | |
NCT06556966: A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects |
|
|
| Not yet recruiting | 1 | 66 | NA | LY03020, LPM787000048 Maleate sustained-release tablet, Placebo, Placebo of LPM787000048 Maleate sustained-release tablet | Luye Pharma Group Ltd. | Schizophrenia, Alzheimer's Disease Psychosis | 05/25 | 08/25 | | |
